We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05067283
Recruitment Status : Recruiting
First Posted : October 5, 2021
Last Update Posted : March 30, 2023
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a study evaluating the efficacy, safety, and pharmacokinetics of MK-1084 in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRASG12C) mutation and MK-1084 plus pembrolizumab in participants with first line (1L) non-small cell lung cancer (NSCLSC) with identified KRASG12C mutation.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: MK-1084 Biological: Pembrolizumab Phase 1

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 264 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination With Pembrolizumab in Subjects With KRASG12C Mutant Advanced Solid Tumors
Actual Study Start Date : December 17, 2021
Estimated Primary Completion Date : February 4, 2026
Estimated Study Completion Date : February 4, 2026

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: MK-1084
Participants will receive MK-1084 daily oral escalating doses of 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 800 mg until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety.
 Drug: MK-1084
Oral dose of 25 or 50 mg tablets
Experimental: Pembrolizumab plus MK-1084
Participants will receive MK-1084 daily oral escalating dose of 25 mg, 50 mg, 100 mg, 200 mg, 400 mg, and 800 mg plus pembrolizumab given as a 200 mg intravenous infusion once every 21-day cycle up to a total of 35 cycles (up to ~24 months). Treatment with MK-1084 will continue until progressive disease or discontinuation. Dosing regimen may be adjusted based on safety.
 Drug: MK-1084
Oral dose of 25 or 50 mg tablets

Biological: Pembrolizumab
Intravenous infusion of 200 mg
Other Names:
  • KEYTRUDA®
  • MK-3475


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Number of participants who experienced a dose-limiting toxicity (DLT) [ Time Frame: Up to ~21 days ]
    A DLT is defined as an event with toxicity including the type, severity, time of onset, time of resolution, and the probable association with study treatment that are not due to pre-existing conditions as defined by the Common Terminology Criteria for Adverse Events Version 5.0 (CTCAE 5.0). Number of participants who experience a DLT will be reported.

  2. Number of participants who experienced an adverse event (AE) [ Time Frame: Up to ~50 months ]
    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who experience an AE will be reported.

  3. Number of participants who discontinued study treatment due to an AE [ Time Frame: Up to ~50 months ]
    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The number of participants who discontinue study treatment due to an AE will be reported.


Secondary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Up to ~50 months ]
    ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1). The percentage of participants who experience a CR or PR as assessed by the investigator based on RECIST 1.1 will be reported.

  2. Duration of response (DOR) [ Time Frame: Up to ~50 months ]
    DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. The DOR as assessed by the investigator will be reported.

  3. Maximum plasma concentration (Cmax) of MK-1084 [ Time Frame: Pre-dose and 1, 2, 4 and 8 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1; Pre-dose on Cycle 1 Day 2, Cycle 1 Day 15, Cycle 2 Day 2, Cycle 3 Day 1, Cycle 6 Day 1 and Day 1 of every third cycle (up to ~50 months). Each cycle = 21 days ]
    Cmax of MK-1084 determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.

  4. Area under the plasma concentration-time curve (AUC) of MK-1084 [ Time Frame: Pre-dose and 1, 2, 4 and 8 hours post-dose on Cycle 1 Day 1 and Cycle 2 Day 1; Pre-dose on Cycle 1 Day 2, Cycle 1 Day 15, Cycle 2 Day 2, Cycle 3 Day 1, Cycle 6 Day 1 and Day 1 of every third cycle (up to ~50 months). Each cycle = 21 days ]
    AUC of MK-1084 determined by blood samples collected pre-dose and at designated timepoints post-dose will be reported.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

For treatment with MK-1084 - Has locally advanced unresectable or metastatic solid-tumor malignancy with histologically OR blood-based confirmation of KRASG12C mutation who has received at least 1 line of therapy for systemic disease.

For treatment with pembrolizumab plus MK-1084

- Has an untreated metastatic NSCLC with histological OR blood-based confirmation of KRASG12C mutation and histologic confirmation of tumor proportion score (TPS) ≥1%.

For all participants:

  • Has measurable disease by RECIST 1.1 criteria.
  • Has adequate organ function.
  • Male participants must be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long-term and persistent basis) and agree to remain abstinent OR must agree to use contraception unless confirmed to be azoospermic.
  • Female participants must not be pregnant or breastfeeding, and at least one of the following conditions applies: is not a woman of child-bearing potential (WOCBP); is a WOCBP and uses a contraceptive method that is highly effective, with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle and must have a negative highly sensitive pregnancy test within 24 hours before the first dose of study intervention.

Exclusion Criteria:

  • Has received chemotherapy, definitive radiation, or biological cancer therapy within 4 weeks (2 weeks for palliative radiation).
  • Has a history of second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 5 years.
  • Has clinically active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Has an active infection requiring systemic therapy.
  • Has a history of human immunodeficiency virus (HIV) and/or hepatitis B or C infections.
  • Has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease.
  • Has a history of interstitial lung disease, noninfectious pneumonitis requiring active steroid therapy, or ongoing pneumonitis.
  • Has an active autoimmune disease requiring systemic therapy.
  • Has not fully recovered from any effects of major surgical procedure without significant detectable infection.
  • Has one or more of the following ophthalmological findings/conditions: intraocular pressure >21 mm Hg and/or any diagnosis of glaucoma; diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion and/or a diagnosis of retinal degenerative disease.
  • Has received live or live-attenuated vaccine within 4 weeks of study start.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05067283


Contacts
Layout table for location contacts
Contact: Toll Free Number 1-888-577-8839 Trialsites@merck.com

Locations
Show Show 42 study locations
Sponsors and Collaborators
Merck Sharp & Dohme LLC
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme LLC
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme LLC
ClinicalTrials.gov Identifier: NCT05067283    
Other Study ID Numbers: 1084-001
MK-1084-001 ( Other Identifier: Merck )
jRCT2041220034 ( Registry Identifier: jRCT )
2021-004024-15 ( EudraCT Number )
First Posted: October 5, 2021    Key Record Dates
Last Update Posted: March 30, 2023
Last Verified: March 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Pembrolizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents